A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2002
10/22/2002	US6468756 Methods of identifying compounds that bind to SNORF25 receptors
10/22/2002	US6468737 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
10/22/2002	US6468546 Compositions and methods for therapy and diagnosis of ovarian cancer
10/22/2002	US6468542 Germination activated Ganoderma lucidum spores and method for producing the same
10/22/2002	US6468541 Natural, non-allergenic, immune system stimulant
10/22/2002	US6468540 Immunotherapeutic stress protein-peptide complexes against cancer
10/22/2002	US6468536 Proteins extracted with perchloric acid from animal organs for preparation of medicaments active against autoimmune diseases, such as atherosclerosis, arthritis, multiple sclerosis, and diabetes; proteins uk 101 and uk 114; sequence
10/22/2002	US6468534 Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use
10/22/2002	CA2147989C Enhancement of xenograft tolerance and porcine cytokines therefor
10/22/2002	CA2095335C Cell growth inhibitors
10/22/2002	CA2073084C The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments
10/17/2002	WO2002082085A2 Conditional autoimmune reaction by natural autoantibodies
10/17/2002	WO2002081747A1 Method of examining steroid responsiveness
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases
10/17/2002	WO2002081661A2 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
10/17/2002	WO2002081636A2 Protein modification and maintenance molecules
10/17/2002	WO2002081522A1 Anti-osteopontin antibody and use thereof
10/17/2002	WO2002081521A2 Osteoprotegerin in milk
10/17/2002	WO2002081519A2 Ifn-thy fusion protein,dna coding therefore,its preparation and application
10/17/2002	WO2002081496A2 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
10/17/2002	WO2002081475A1 Jun kinase inhibitors
10/17/2002	WO2002081463A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002	WO2002081461A1 Piperazine derivatives as tachykinin antagonists
10/17/2002	WO2002081457A1 `1,4!-diazepane-1-carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081430A2 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	WO2002080987A1 Anti-cd19 immunotoxins
10/17/2002	WO2002080982A2 Nucleic acid mucosal immunization
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080976A2 Hsa-free formulations of interferon-beta
10/17/2002	WO2002080966A2 Method for producing a vaccine containing autologous antibodies
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080942A1 Pharmaceutical composition comprising copper, salicyclic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080925A1 Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
10/17/2002	WO2002080908A1 Azolylcarbynol derivatives of aryl (or heteroaryl) for the treatment of respiratory diseases
10/17/2002	WO2002080907A1 Combination of lactacystin analog and immunosuppressive drug for the prolongation of allograft survival
10/17/2002	WO2002080896A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080851A2 Chimeric vaccines
10/17/2002	WO2002080842A2 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis
10/17/2002	WO2002060924A3 Identification and applications of porcine reproductive and respiratory syndrome virus host susceptibility factor(s) for improved swine breeding and development of a non-simian recombinant cell line for propagation of the virus and a target for a novel class of antiviral compounds
10/17/2002	WO2002059114A9 Lfa-1 antagonist compounds
10/17/2002	WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002	WO2002036733A9 Cd36 as a heat shock protein receptor and uses thereof
10/17/2002	WO2002036605A9 Estrone-derivatives having cytoprotective activity
10/17/2002	WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002017891A3 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2001098354A3 Human receptors
10/17/2002	WO2001098323A3 G-protein coupled receptors
10/17/2002	WO2001090151A3 Human receptor proteins; related reagents and methods
10/17/2002	WO2001074404A3 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
10/17/2002	WO2001060847A9 Avirulent, immunogenic flavivirus chimeras
10/17/2002	WO2001058922A9 Method and compositions for treating hepatocellular cancer
10/17/2002	WO2001058241A9 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
10/17/2002	WO2001055370A9 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
10/17/2002	WO2001054723A9 Therapeutic method for reducing angiogenesis
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	WO2001040497A3 Method for obtaining nucleic acids from an environment sample
10/17/2002	US20020152481 Genetic engineering; qualitative analysis
10/17/2002	US20020151698 For diagnosis, prevention, and treatment of cancer, and neurological and immune disorders
10/17/2002	US20020151695 Transforming growth factor-beta-related molecules and uses thereof
10/17/2002	US20020151688 Generating virally deactivated immunoglobulin; obtain mixture containing immunoglobulin, suspend in carbohydrate solution, reduce impurities, apply column, filter, recover efluent, inactivate with virus, preciptate and recover immunoglobulin
10/17/2002	US20020151682 Biological products
10/17/2002	US20020151679 Peptide for use in the treatment of infections, viral and cancer diseases
10/17/2002	US20020151596 Novel process to prepare 2-aminoindan derivatives
10/17/2002	US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002	US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002	US20020151573 Anticancer agents
10/17/2002	US20020151553 Such as 4-(4-chlorophenyl)1-(3-(5-cyano-5H-dibenzo(a,d) cycloheptene-5-yl)propyl)piperidin-4-ol for treatment of diseases associated with aberrant leukocyte recruitment and/or activation
10/17/2002	US20020151547 Substituted phenyl-piperidine methanone compounds
10/17/2002	US20020151545 Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and metastasis inhibitors in treating cancer
10/17/2002	US20020151494 Novel amino acid sequences for human semaphorin-like polypeptides
10/17/2002	US20020151493 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
10/17/2002	US20020151488 G-CSF analog compositions and methods
10/17/2002	US20020151485 Methods and compositions for modulating fertility
10/17/2002	US20020151483 C3b/C4b complement receptor-like molecules and uses thereof
10/17/2002	US20020151475 Compounds and methods for modulating cell adhesion
10/17/2002	US20020151049 Self-enhancing, pharmacologically controllable expression systems
10/17/2002	US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002	US20020150993 Nucleotide sequences coding polypeptide for use in the treament of apoptosis, inflammatory or autoimmune diseases
10/17/2002	US20020150992 Nucleotide sequences coding polypeptide for us ein the treatment of immunological disorders
10/17/2002	US20020150980 Nucleotide sequences coding protein for use in the treatment of asthma, parkinson's, heart, hypotension, osteporosis and urogenital disorders
10/17/2002	US20020150977 Nucleotide sequences coding protein for use in the diagnosis, treatment and prevention of autoimmune, cell proliferative and inflammatory diseases
10/17/2002	US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002	US20020150600 Conjugate, its preparation and use
10/17/2002	US20020150586 Novel amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
10/17/2002	US20020150585 Intensify immunology response; polysaccharide complex
10/17/2002	US20020150577 Transforming growth factor; transgenic animal; increas ratios of muscle mass
10/17/2002	US20020150570 Anti-CCR2 antibodies and methods of use therefor
10/17/2002	US20020150565 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/17/2002	US20020150562 Viral preparations, vectors, immunogens, and vaccines
10/17/2002	US20020150560 Treatment of Il-10 deficiencies
10/17/2002	US20020150559 Binding of human antigens
10/17/2002	US20020150551 Protease surface treatment
10/17/2002	DE10201458A1 New proteins involved in isoprenoid biosynthesis, useful in screening for inhibitors, also new intermediates, potential therapeutic agents, nucleic acids and antibodies
10/17/2002	DE10164711A1 Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen Use of sugar phosphates, sugar phosphate analogs, amino acids and / or amino acid analogs to modulate the glycolytic enzyme complex, the malate aspartate shuttle and / or the transaminases
10/17/2002	DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections

1 ... 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 ... 1172